Ceftriaxone, sold under the trade name Rocephin, is an antibiotic useful for the treatment of a number of bacterial infections. This includes pneumonia, ear infections, skin infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, septisis, bone and joint infections, intra-abdominal infections, and meningitis. It is also used preoperatively to reduce the risk of postoperative infections. It is administered by intravenous or intramuscular injection.

Starting at
|
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)->2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| Pronunciation | /ˌsɛftraɪˈæksoʊn/ |
| Trade names | Rocephin, Epicephin, Arixon, Elcefrin |
| AHFS/Drugs.com | monograph |
| Pregnancy category |
AU: B1 US: B (No risk in non-human studies) |
| Legal status | AU: S4 (Prescription only) |
| Routes of administration |
Intravenous, intramuscular |
| Bioavailability | n/a |
| Metabolism | Negligible |
| Biological half-life | 5.8–8.7 hours |
| Excretion | 33–67% renal, 35–45% biliary |
| CAS Number | 73384-59-5 |
| ATC code | J01DD04 |
| PubChem | CID: 5479530 |
| IUPHAR/BPS | 5326 |
| DrugBank | DB01212 |
| ChemSpider | 4586394 |
| UNII | 75J73V1629 |
| KEGG | D07659 |
| ChEBI | CHEBI:29007 |
| ChEMBL | CHEMBL161 |
| Formula | C18H18N8O7S3 |
|---|---|
| Molecular mass | 554.58 g/mol |
|
SMILES[show]
|
|
|
InChI[show]
|
|